The contribution of Douglas Altman’s research to the EVIDENCE Journal

Lucas Helal
Federal University of Rio Grande do Sul. Porto Alegre, Rio Grande do Sul, Brazil. ORCID: 0000-0002-6900-7185. lucas.helal@ufrgs.br

This journal was born vastly inspired in most of Douglas Altman’s research and ideals. Dr. Altman will not be only remembered by his worldwide-spread research pieces. He will be remembered by his ahead-of-time thinking; by his criticism as an effort for a better medical research; and also by his efforts to improve science integrity and reproducibility – that said, all of these with an unparalleled importance beyond scientific pieces that all of us need to have in mind as concepts for practicing, inspiring and guidance. As the associate-editor of the Statistics section of the Evidence Journal, I am more than glad to have the opportunity to comment a thing about his legacy, which inspired me and contributed to a great part of my training; and that will continue all over my career.

In the last years, Dr. Altman had been working in efforts to improve scientific transparency and reproducibility, mainly by the development of scientific reporting guidelines. For example, he was one of the co-founders of the Enhancing the Quality and Transparency of Health Research (EQUATOR) Network, and also had co-authorships in the most important guidelines, such as the Consolidated Standards for Reporting Trials (CONSORT Statement)¹; the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA Statement)²; or the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE Statement)³. Pretty important to say, most of the leading biomedical journals today adhere to the mandatory use of reporting guidelines, as the same recommended by the International Committee of Medical Journal Editors. Notwithstanding, we can say that he predicted the poor reporting several years before in his seminal piece about the poor medical research that I will comment thereafter⁴.

Traditionally, Dr. Altman is recognized by the development of statistical methods, mainly the analysis of agreement between two different methods to measure the same signal – i.e., the Bland & Altman plot⁵; and also by his countless educational scientific pieces with his long-standing collaborator Martin Bland, in which more than 50 statistical notes were published over time in the British Medical Journal (The BMJ)⁶-⁸. Many of these helped us while students, epidemiologists, care-providers, professors and researchers and will continue to help the future generation.
The scientific community needs to acknowledge him by his contribution to developing a simple and friendly statistics to measure the risk of bias of randomized clinical trials in systematic reviews; or for the $I^2$ statistics, which substituted the $Q^2$ statistics years later also through a friendly way to assess heterogeneity of results in meta-analyses, that is widespread through almost every single available statistical package. Nonetheless, another seminal work that could be referred to him is how to interpret results of asymmetry in meta-analyses, in which the so common mislead concept between asymmetry and publication bias among scientists was commented as well.

In respect to his criticism for the way that medical research has been conducted, it can be identified not only by his conference talks, likely by his so-called quote about a part of the medical research that is done by non-research-trained physicians: “The difference between the agronomy and the medical research is that the first one is never done by farmers”, or by the personal interactions in which he disclaimed his thoughts. The literature is plenty of pieces in which his mind-thinking is clear and evident. In 1994, he published his seminal editorial – and perhaps his most influential piece entitled “The scandal of poor medical research”, starting his text with a concept that, years later, became the tone in the scientific community: “We need less research, better research, and research done for the right reasons.” In this piece, he disclaimed the problem of misleading medical research through small and unrepresentative sample sizes, incorrect methods of analysis, the “publish or perish” concept among scientists and the spin of interpretation. Not surprisingly, the meta-research quantitatively confirmed his postulates, decades after.

Today, many concepts that can seriously jeopardize scientific results across different study designs and that are completely accepted by the scientific community had his contributions. For example, he provided empirical evidence of how the lack of blinding (a) and the inadequate allocation concealment (b) could affect effect sizes in randomized clinical trials. For regression analysis, he pointed out how the misuse of dichotomization of continuous data could affect coefficients. Nonetheless, some important topics of global epidemiology had his contributions. Here, we can cite his efforts to improve maternal and newborn health, mainly by protective effects of magnesium sulphate to reduce pre-eclampsia risk during pregnancy and by his work with the INTERGROWTH-21th, mostly developing international fetal and newborn growth charts.

Dr. Altman died in 3rd June 2018 by bowel cancer at 70 years old.

Competing interests

No financial, legal or political competing interests with third parties (government, commercial, private foundation, etc.) were disclosed for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.).

References

1. Moher D, Schulz KF, Altman DG, CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001; 134(8):657-62. doi: 10.7326/0003-4819-134-8-200104170-00011

2. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analysis: the PRISMA Statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097

3. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vanderbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. doi: 10.1371/journal.pmed.0040296

4. Altman DG. The scandal of poor medical research. BMJ. 1994;308:283. doi: 10.1136/bmj.308.6924.283

5. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-10. doi: 10.1016/S0140-6736(86)90837-8

6. Bland JM, Altman DG. Cronbach’s alpha. BMJ. 1997;314:572. doi: 10.1136/bmj.314.7080.572

7. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ. 1995;310:170. doi: 10.1136/bmj.310.6973.170
8. Altman DG, Bland JM. Diagnostic tests 1: Sensitivity and specificity. BMJ. 1994;308:1552. doi: 10.1136/bmj.308.6943.1552

9. Higgins JP, Altman DG, Goetzsche PC, Juni P, Moher D, Oxman AD et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928

10. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557

11. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. doi: 10.1136/bmj.d4002

12. Fanelli D. How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. PLoS One. 2009;4(5):e5738. doi: 10.1371/journal.pone.0005738

13. Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC et al. Epidemiology and reporting characteristics of systematic reviews of biomedical research: a cross-sectional study. PLoS Med. 2016;13(5):e1002028. doi: 10.1371/journal.pmed.1002028

14. Page MJ, Higgins JP, Clayton G, Sterne JA, Hrobjartsson A, Savovic J. Empirical evidence of study design biases in randomized trials: systematic review of meta-epidemiological studies. PLoS One. 2016;11(7):e0159267. doi: 10.1371/journal.pone.0159267

15. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336(7644):601-5. doi: 10.1136/bmj.39465.451748.AD

16. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25:127-41. doi: 10.1002/sim.2331

17. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J et al; Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877-90. doi: 10.1016/S0140-6736(02)08778-0

18. Villar J, Cheikh Ismail L, Victoria CG, Ohuma EO, Bertino E, Altman DG et al. International Fetal and Newborn Growth Consortium for the 21st Century [INTERGROWTH-21st]. International standards for newborn weight, length, and head circumference by gestational age and sex: newborn cross-sectional study of the INTERGROWTH-21st project. Lancet. 2014;384(9946):857-68. doi: 10.1016/S0140-6736(14)60932-6